Don’t Get Caught Up In Reefer Madness: The Charles Schwab Corporation (SCHW), AbbVie Inc. (ABBV)

The stock of The Charles Schwab Corporation (NYSE:SCHW) recorded -17.07% downtrend from the beginning of this year till date. The 12-month potential price target for The Charles Schwab Corporation is set at $55.69. This target means that the stock has an upside potential to increase by 30.73% from the current trading price. SCHW went down by -$0.41 now trading at $42.6. Their shares witnessed a 1.4% increase from the 52-week low price of $42.01 they recorded on 2018-12-06. Even though it is still -41.36% behind the $60.22 high touched on 2018-05-21. The last few days have been rough for the stock, as its price has decreased by -6.7% during the week. It has also performed poorly over the past three months, as it lost around -13.96% while it has so far retreated around -16.11% during the course of a year.

When giving their opinion, around 63.16% of Wall Street analysts, which represents 12 out of 19 rated the stock as a Buy. 6 brokerage firms of the remaining 31.58% rated the stock as a Hold with 1 analyst rating it as a sell. Overall, the number of aggregate SCHW shares held by institutional investors represents 81.4% of total shares. 95 institutions entered new The Charles Schwab Corporation (NYSE:SCHW) positions, 542 added to their existing positions in these shares, 445 lowered their positions, and 69 exited their positions entirely.

The Charles Schwab Corporation (SCHW) trade volume has increased by 63.4% as around 14,288,473 shares were sold when compared with its 50-day average volume of traded shares which is 8,744,580. At the moment, SCHW is witnessing a downtrend, as it is trading -7.44% below its 20-day SMA, -9.7% below its 50-day SMA, and -17.92% below its 200-day SMA. The company runs an ROE of roughly 17.7%, with financial analysts predicting that their earnings per share growth will be around 27.52% per annum for the next five year. This will be compared to the 18.9% increase witnessed over the past five years.

The first technical resistance point for The Charles Schwab Corporation (NYSE:SCHW) will likely come at $43.16, marking a 1.3% premium to the current level. The second resistance point is at $43.71, about 2.54% premium to its current market price. On the other hand, inability to breach the immediate hurdles can drag it down to $40.57, the lower end of the range. SCHW’s 14-day MACD is -1.3 and this negative figure indicates a downward trading trend. The company’s 14-day RSI (relative strength index) score is 35.35, which shows that its stock has been neutral. The 20-day historical volatility for the stock stands at 31.17 percent, which is low when compared to that of the 50-day’s 32.66 percent.

The shares of AbbVie Inc. (NYSE:ABBV) has decreased by -0.24%, and now trading at $90.33 on the Wall Street in the intra-day deal, with their shares traded now around 8,513,538. This is a rise of 1,807,594 shares over the average 6,705,944 shares that were traded daily over the last three months. The stock that is trading at $90.33 went higher by 16.55% from its 52-week low of $77.5 that it attained back on 2018-11-01. The stock recorded a 52-week high of $125.86 nearly 315 days ago on 2018-01-26.

ABBV stock has performed well over the past 30 days, as it added 9.38% while its price plunged by -6.6% year-to-date (YTD). Looking at the last few days, it has been good for the stock, as it rose 1.56% over the last week. The stock’s 12-month potential target price is now at $100.58. This means that the stock price might likely increase by 11.35% from its current trading price.8 out of 20 Wall Street analysts which represents 40% rated the stock as a buy while the remaining 45 rated it as a hold, with 15 of analysts rating it as a sell.

AbbVie Inc. (NYSE:ABBV) has been utilizing an ROE that is roughly 0%, with stock analysts predicting that the company’s EPS for the next five years will go up by 16.87% per year, following the 1.2% raise that was witnessed during the past five years. The stock at the moment is on a uptrend, trading 1.74% above its 20-day SMA, 1.88% above its 50-day SMA, and -6.37% below its 200-day SMA. In percentage terms, the aggregate AbbVie Inc. shares held by institutional investors is 72.2%. 68 institutions jumped in to acquire AbbVie Inc. (ABBV) fresh stake, 812 added to their current holdings in these shares, 986 lowered their positions, and 96 left no stake in the company.

The stock’s 9-day MACD is 1.82 and this positive figure indicates an upward trading trend. The company’s 9-day RSI score is 54.37, which shows that its stock has been neutral. The 20-day historical volatility for the shares stand at 32.81 percent, which is less when compared to that of the 50-day’s 33.42 percent. On the daily chart, we see that the stock could reach the first level of resistance at $91.48, sporting a 1.26% premium to the current level. The next resistance point is at $92.64, representing nearly 2.49% premium to the current market price of AbbVie Inc. (ABBV). On the other hand, failure to breach the immediate hurdles can drag it down to $86.02, the lower end of the range.